ACUTE GRAFT-VERSUS-HOST DISEASE
Clinical trials for ACUTE GRAFT-VERSUS-HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new ACUTE GRAFT-VERSUS-HOST DISEASE trials appear
Sign up with your email to follow new studies for ACUTE GRAFT-VERSUS-HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to tame GVHD with fewer steroid side effects
Disease control TerminatedThis study tested a combination of three drugs (ruxolitinib, uhCG/EGF, and steroids) to treat a severe complication called acute graft-versus-host disease (GVHD) that can occur after a stem cell transplant. The goal was to find the lowest effective steroid dose to reduce side eff…
Matched conditions: ACUTE GRAFT-VERSUS-HOST DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Pediatric GVHD drug combo trial ends early after enrolling just 2 kids
Disease control TerminatedThis study tested a drug called itacitinib combined with steroids to treat acute graft-versus-host disease (aGVHD) in children. aGVHD is a serious complication after a stem cell transplant where donor cells attack the child's body. The trial was stopped early after only 2 partici…
Matched conditions: ACUTE GRAFT-VERSUS-HOST DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 13, 2026 16:03 UTC